Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

European Commission approves Novo Nordisk's Wegovy (semaglutide) pill for obesity and overweight adults
Small molecule, metabolic, GLP-1 receptor agonist, obesity, semaglutide - Read more

FDA approves Merck & Co.'s Lipfendra (enlicitide), first oral PCSK9 inhibitor pill, for hypercholesterolemia including heterozygous familial hypercholesterolemia
Small molecule, cardiovascular, macrocyclic peptide, hypercholesterolemia, PCSK9 inhibitor - Read more

EpilepsyGTx, ClearPoint Neuro partner on targeted gene therapy delivery for focal refractory epilepsy trials
Research collaboration, neurological, gene therapy, rare disease, drug delivery - Read more

Chai Discovery, Argenx collaborate to advance AI-driven de novo antibody discovery for immunology targets
Research collaboration, autoimmune, AI/ML, antibody, drug discovery - Read more

Cordex Biologics, FarmaMondo partner on Zemcelpro distribution in Argentina, Hong Kong and Singapore
Distribution agreement, hematological malignancies, cell therapy, commercialization, early access - Read more

Samsung Bioepis, Organon expand biosimilar commercialisation agreement to broaden access in Australia
Commercialisation agreement, biosimilar, manufacturing, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Merck & Co.'s Keytruda (pembrolizumab) becomes first PD-1 inhibitor to show Ph3 benefit as single agent in front-line mismatch repair deficient endometrial cancer
Antibody, cancer, monoclonal antibody, endometrial cancer, PD-1 inhibitor, dMMR - Read more

Veradermics' VDPHL01 (minoxidil) shows positive Ph2 results for female pattern hair loss
Small molecule, dermatological, minoxidil, androgenetic alopecia, female pattern hair loss - Read more

InnoCare Pharma's (soficitinib) TYK2 inhibitor meets primary endpoint in Ph2 nonsegmental vitiligo trial
Small molecule, autoimmune, TYK2 inhibitor, vitiligo, JAK inhibitor - Read more

Kairos Pharma's ENV-105 (carotuximab) shows clean Ph1 interim safety profile in epidermal growth factor receptor-mutated non-small cell lung cancer
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, EGFR mutation, combination therapy- Read more

J&J's Spravato hits $584M in Q2 with 40% growth as psychedelic rivals approach market
Small molecule, neurological, competitive, revenue impact - Read more

Johnson & Johnson raises 2026 guidance as Tremfya hits $2B and Icotyde launch exceeds expectations
IL-23 inhibitor, autoimmune, revenue impact, financial - Read more

Braveheart Bio files for Nasdaq IPO to advance phase 3 Hengrui-licensed HCM drug
Cardiovascular, small molecule, hypertrophic cardiomyopathy, clinical-stage - Read more

AdvanCell raises $315M Series D, advancing lead-212 targeted alpha therapy toward Phase III
Radiopharmaceuticals, oncology, targeted alpha therapy, prostate cancer, clinical-stage, manufacturing - Read more

Vogenx files for IPO to fund phase 2b SGLT1 inhibitor for post-bariatric hypoglycemia
Metabolic disease, small molecule, clinical-stage, SGLT1 inhibitor- Read more

Telix Pharmaceuticals opens Australia's first integrated radiopharmaceutical research, manufacturing, and treatment facility in Melbourne
Radiopharmaceutical, oncology, operational, strategic - Read more

Eli Lilly to acquire AtaiBeckley for up to $3.8B, marking pharma's first psychedelics push into depression treatment
Psychedelic compound, neurological, major transaction, strategic - Read more

Johnson & Johnson receives UK MHRA approval for AKEEGA in BRCA1/2-mutated metastatic prostate cancer
Small molecule, oncology, PARP inhibitor, precision medicine - Read more

J&J restructures pharma supply chain with $750M overhaul amid $55B US manufacturing push
Supply chain restructuring, pharma manufacturing, operational, cost reduction, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

J&J discontinues (JNJ-1887) gene therapy targeting complement CD59 pathway after Ph2b geographic atrophy trial failure
Gene therapy, ophthalmology, AAV gene therapy, geographic atrophy, complement pathway, age-related macular degeneration - Read more

Sanofi sues Pfizer and Moderna over LNP patent infringement tied to Translate Bio acquisition
mRNA vaccine, infectious disease, competitive, major transaction - Read more

Medtronic recalls 102 lots of Harmony catheter delivery system over life-threatening tip detachment risk
Medical device, cardiovascular, operational, safety recall - Read more

Pfizer scraps mesothelin-targeted Ph1 trial of (SGN-MesoC2) for advanced solid tumors due to strategic reprioritization
Antibody-drug conjugate, cancer, solid tumors, mesothelin, non-small cell lung cancer - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here